newsfilter
← Earnings
Earnings Releases·

Tango Therapeutics — Third Quarter 2026 Earnings Summary

Tango Therapeutics reported a net loss of $68.4 million for the third quarter of 2026, driven by increased research and development expenses related to its vopimetostat and TNG456 clinical programs. The company holds $977.5 million in cash and cash equivalents as of September 30, 2026, which is expected to fund its current operating plan. Clinical highlights include promising Phase 1/2 data for the combination of vopimetostat and daraxonrasib in pancreatic cancer, showing an 82% objective response rate and an 88% nine-month progression-free survival rate. Based on these results, Tango plans to initiate a registrational Phase 3 study of this combination in front-line MTAP-deleted pancreatic cancer during the first half of 2027.

Company
TANGO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology